Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - cālis - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Latvija - latviešu - Zāļu valsts aģentūra

gedeon richter plc., hungary - fentanils - transdermālais plāksteris - 50 mikrogrami/stundā

Latvija - latviešu - Zāļu valsts aģentūra

gedeon richter plc., hungary - fentanils - transdermālais plāksteris - 75 mikrogrami/stundā

Latvija - latviešu - Zāļu valsts aģentūra

gedeon richter plc., hungary - fentanils - transdermālais plāksteris - 100 mikrogrami/stundā

Latvija - latviešu - Zāļu valsts aģentūra

gedeon richter plc., hungary - fentanils - transdermālais plāksteris - 25 mikrogrami/stundā

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine, lamivudīnu, tenofovir disoproxil fumarate - hiv infekcijas - antivirals for treatment of hiv infections, combinations - delstrigo ir indicēts, lai ārstētu pieaugušos ar hiv inficēti 1 bez pagātnes vai tagadnes pierādījumus par pretestību nnrti klases, lamivudīnu, vai tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiski līdzekļi - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiski līdzekļi - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostatas audzēji - endokrīnā terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohidrāts, cilastatin nātrija, relebactam monohidrāts - gram-negatīvo baktēriju infekcijas - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 un 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4. un 5.. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.